Tara Gangadhar, MD | Authors


Dr. Tara Gangadhar on Single-Agent Versus Dual Immunotherapy Approaches in Melanoma

March 15, 2016

Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.